Vol 7, No 2 (2021)
Guidelines / Expert consensus
Published online: 2021-06-30
Postępowanie w przypadku podejrzanych zmian skórnych. Praktyczne wskazówki dla lekarzy specjalności nieonkologicznych
DOI: 10.5603/FD.2021.0009
Forum Dermatologicum 2021;7(2):27-36.
Abstract
Not available
References
- Rutkowski P, Owczarek W. Dermatochirurgia. Bibloteka chirurga onkologa. Tom XII. Via Medica, Gdańsk 2018.
- Rutkowski P, Wysocki P, Nasierowska-Guttmejer A, et al. Cutaneous melanoma. Oncol Clin Pract. 2020; 16(4): 163–182.
- Wysocki WM, Wójtowicz E. Pacjent ze zmianą barwnikową. Postępowanie diagnostyczne dla dermatologów i chirurgów wraz z kartą konsultacyjną pacjenta; karta pacjent ze zmiana barwnikowa 2020 10.pdf (immu-no onkologia.pl).
- Berwick M, Buller DB, Cust A, et al. Melanoma Epidemiology and Prevention. Cancer Treat Res. 2016; 167: 17–49.
- O’Neill CH, Scoggins CR. Melanoma. J Surg Oncol. 2019; 120(5): 873–881.
- Kamińska-Winciorek G, Pilśniak A. The role of dermoscopy in dermato-oncological diagnostics – new trends and perspectives. Nowotwory. Journal of Oncology. 2021; 71(2): 103–110.
- Michielin O, van Akkooi ACJ, Ascierto PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(12): 1884–1901.
- NCCN Guidelines: Melanoma: Cutaneous. 1/2021. Available online 29/1/2021. www.nccn.org.
- Wong S, Faries M, Kennedy E, et al. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(4): 399–413.
- Wysocki W, Rutkowski P. Management of metastases in regional lymph nodes in melanoma patients in 2019. Nowotwory. Journal of Oncology. 2019; 69(3-4): 108–110.
- Angeles CV, Kang R, Shirai K, et al. Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma. Br J Surg. 2019; 106(6): 672–681.
- Leiter U, Stadler R, Mauch C, et al. German Dermatologic Cooperative Oncology Group (DeCOG). Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016; 17(6): 757–767.
- Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel ode Metastasis in Melanoma. N Engl J Med. 2017; 376(23): 2211–2222.
- Leiter U, Stadler R, Mauch C, et al. German Dermatologic Cooperative Oncology Group. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019; 37(32): 3000–3008.
- Rutkowski P, Wysocki W, Świtaj T, et al. New developments in the perioperative treatment of melanomas with locoregional advancement. Nowotwory. Journal of Oncology. 2019; 69(3-4): 97–102.
- Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020; 383(12): 1139–1148.
- Ascierto P, Vecchio MD, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020; 21(11): 1465–1477.
- Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020; 38(33): 3925–3936.
